1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
V Scholar or Translational or All-Star – 2026 Pediatric Cancer Research Grants is a grant from V Foundation for Cancer Research that funds innovative pediatric cancer research at invited institutions across the United States. Three grant mechanisms are offered: V Scholar grants ($800,000 over 4 years), Translational grants ($800,000 over 4 years), and All-Star grants ($1,000,000 over 5 years).
The V Foundation funds the most promising cancer research projects focused on improving diagnosis, preventing recurrences, and defeating cancer. Eligible applicants must be faculty at assistant professor level or above at an invited institution and be US citizens or hold legal work authorization. Previous V Foundation grant recipients may be eligible for the All-Star track.
This is a closed RFA — only invited institutions may apply.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Our Cancer Research Grants | V Foundation Skip to content The Latest Jay Harris: “Without the Research, I’m Not Here. ” 100% to Our Mission of Victory Over Cancer®!
Eric Doust: “The Beginning of a Long Story” American Association for Cancer Research Announces 2026 Academy Fellows Leadership & Collaboration Diversity, Equity and Inclusion The V Foundation’s grant making model ensures the most promising cancer research projects at state-of-the-art facilities around the country are funded.
Cancer research grants are awarded to innovative researchers with the most cutting-edge ideas on how to improve cancer diagnosis methods, prevent cancer recurrences or defeat cancer. 100% of direct donations are used to fund projects we identify as the most likely to help men, women and children diagnosed with cancer. Reprogramming Differentiation Trajectories to Overcome FLT3 Inhibitor Resis...
Dissecting sensory nerve contributions in pancreatic inflammation and malig... Targeting Glutamine Metabolism in Soft Tissue Sarcoma Tumor-Infiltrating B Cells: Decoding Metabolic and Contact-Mediated Signals... A Data-Driven Approach to Uncover a Cysteine Sensor Regulating Cancer Ferro...
The systemic impact of breast cancer: understanding and reprogramming tumou... A New Metaplastic Cell Type in the Stomach: Elucidating the Triggers and Dr... Targeting histone acetyltransferase complexes in oncogenic fusion protein-d...
Overcoming Acquired Resistance to Antibody Drug Conjugate (ADC) Therapy in ... The role of tRNA cleavage by Angiogenin in controlling Kaposi sarcoma-assoc... Harnessing Commensal Microbes for Cancer Immunotherapy: Mechanism and Thera...
Targeting Obesity and Progesterone Resistance to Prevent Endometrial Cancer Systematic dissection of MECOM cofactor binding to identify druggable targe... Dual Targeting of Cancer Cells and Stromal Interactions in Lymphoma to Over... Developing tools to unlock the role of the pulmonary microbiome in lung cancer Targeting CDK7 in Patients with Resectable or Borderline Resectable Basal-Like Pancreatic Ductal...
Controlling treatment toxicity in ovarian cancer to prime the patient for tumor... Defining microbial control of immune recovery after cancer treatment A novel therapeutic strategy in AL amyloidosis and multiple myeloma: targeting immunoglobulin...
Stalling cancer at the ribosome Mechanisms of mutant ASXL1-driven clonal hematopoiesis and myeloid leukemia Identifying Post-Transcriptional Regulators of Metastasis TransTAC Platforms for Targeted Membrane Protein Degradation and Drug Delivery Jennifer Rosenbluth, MD, PhD When Tamoxifen Fails: New Targets for Breast Cancer Prevention Targeting ABL1/2 and DDR1 tyrosine kinases for treating NRAS-mutant melanoma Unleashing the anti-tumor potential of B cells and tertiary lymphoid structures for...
Leveraging Newly Discovered Vulnerabilities of EGFR-Driven Lung Adenocarcinomas for Clinical Impact *In... Targeting PGAM1 to Enhance CAR-T Cell Therapy: A Novel Strategy for Pancreatic...
Mechanisms of checkpoint receptor inhibitor-dependent immune-related Adverse Events in skin and gut Christina Von Roemeling, PhD Reprogramming Glioblastoma: Harnessing Adeno-Associated Virus for Immune Gene Therapy Identifying metabolic vulnerabilities of breast epithelium in BRCA1 mutation carriers with obesity... Statistics Statistics The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing Marketing The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes. Manage {vendor_count} vendors Accept Deny View preferences Save preferences View preferences Statistics Statistics The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing Marketing The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes. Manage {vendor_count} vendors Accept Deny View preferences Save preferences View preferences Manage consent Manage consent
According to the current listing, eligibility includes: Faculty at assistant professor level or above at invited institutions only; must be US citizen or have legal work permit; previous V Foundation grant recipients eligible for All-Star track. Confirm the full requirements in the official notice before applying.
The current listing shows $800,000–$1,000,000 over 4–5 years. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was March 11, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
V Scholar or Translational or All-Star – 2026 Pediatric Cancer Research Grants is funded by V Foundation for Cancer Research. Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
The Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articleCDC-RFA-DP-27-0023 puts the National Breast and Cervical Cancer Early Detection Program, the National Comprehensive Cancer Control Program, and the National Program of Cancer Registries into a single competition closing February 5, 2027. Three statutorily separate eligibility pools, one application deadline, and an award count that maps onto the incumbent footprint. Here is how to read that.
Read articleCDMRP reissued the FY26 BCRP Breakthrough Award Levels 1 and 2 and the Clinical Research Extension Award on September 3, 2026, with a November 4 pre-application deadline and a November 18 full application deadline. Round one closed July 8. The arithmetic across both windows accounts for nearly the entire FY26 appropriation — which tells you what kind of second chance this is.
Read article